7057-33-2

7057-33-2结构式
7057-33-2结构式
  • 常用中文名:3'-脱氧胞苷
  • 常用英文名:3'-Deoxycytidine
  • CAS号:7057-33-2
  • 分子式:C9H13N3O4
  • 分子量:227.22
  • 相关类别: 生物化工 核苷类药物 脱氧核苷酸及其类似物
  • 发布时间:2018-05-16 08:00:00
  • 更新时间:2024-01-03 19:27:26
  • 4-氨基-1-((2R,3R,5S)-3-羟基-5-(羟甲基)四氢呋喃-2-基)嘧啶-2(1H)-酮(3'-脱氧胞苷)是嘌呤核苷类似物。嘌呤核苷类似物具有广泛的抗肿瘤活性,靶向惰性淋巴系统恶性肿瘤。这一过程中的抗癌机制依赖于抑制DNA合成、诱导细胞凋亡等[1]。

化源商城直购

中文名 3-脱氧胞苷
英文名 3'-deoxycytidine
英文别名 4-Amino-1-[(2R,3R,5S)-3-hydroxy-5-(hydroxymethyl)tetrahydro-2-furanyl]-2(1H)-pyrimidinone
4-Amino-1-(3-deoxy-β-D-erythro-pentofuranosyl)pyrimidin-2(1H)-on
3'-deoxy-cytidine
3'-Deoxycytidine
3'-deoxyribicytidine
3'-Deoxy-D-cytidine
3'-deoxycytidine free base
Cytidine, 3'-deoxy-
描述 4-氨基-1-((2R,3R,5S)-3-羟基-5-(羟甲基)四氢呋喃-2-基)嘧啶-2(1H)-酮(3'-脱氧胞苷)是嘌呤核苷类似物。嘌呤核苷类似物具有广泛的抗肿瘤活性,靶向惰性淋巴系统恶性肿瘤。这一过程中的抗癌机制依赖于抑制DNA合成、诱导细胞凋亡等[1]。
相关类别
参考文献

[1]. Robak T, Robak P. Purine nucleoside analogs in the treatment of rarer chronic lymphoid leukemias. Curr Pharm Des. 2012;18(23):3373-88.  

密度 1.7±0.1 g/cm3
沸点 497.6±55.0 °C at 760 mmHg
分子式 C9H13N3O4
分子量 227.22
闪点 254.8±31.5 °C
精确质量 227.090607
PSA 110.60000
LogP -1.70
蒸汽压 0.0±2.9 mmHg at 25°C
折射率 1.720
储存条件 2-8°C
分子结构

1、 摩尔折射率:51.79

2、 摩尔体积(m3/mol):131.1

3、 等张比容(90.2K):389.4

4、 表面张力(dyne/cm):77.8

5、 极化率(10-24cm3):20.53

更多

一、物性数据

性状:不可用

密度(g/mL,25/4℃):不可用

相对蒸汽密度(g/mL,空气=1):不可用

熔点(ºC):不可用

沸点(ºC,常压):不可用

沸点(ºC,5.2kPa):不可用

折射率:不可用

闪点(ºC):不可用

比旋光度(º):不可用

自燃点或引燃温度(ºC):不可用

蒸气压(kPa,25ºC):不可用

饱和蒸气压(kPa,60ºC):不可用

燃烧热(KJ/mol):不可用

临界温度(ºC):不可用

临界压力(KPa):不可用

油水(辛醇/水)分配系数的对数值:不可用

爆炸上限(%,V/V):不可用

爆炸下限(%,V/V):不可用

溶解性:不可用


Section1. IDENTIFICATION OF THE SUBSTANCE/MIXTURE
Product identifiers
: 3′-Deoxycytidine
Product name
CAS-No.: 7057-33-2
Relevant identified uses of the substance or mixture and uses advised against
Identified uses: Laboratory chemicals, Manufacture of substances



Section2. HAZARDS IDENTIFICATION
Classification of the substance or mixture
Not a hazardous substance or mixture according to Regulation (EC) No. 1272/2008.
This substance is not classified as dangerous according to Directive 67/548/EEC.
Label elements
The product does not need to be labelled in accordance with EC directives or respective national laws.
Other hazards - none

Section3. COMPOSITION/INFORMATION ON INGREDIENTS
Substances
Formula: C9H13N3O4
Molecular Weight: 227,22 g/mol

Section4. FIRST AID MEASURES
Description of first aid measures
If inhaled
If breathed in, move person into fresh air. If not breathing, give artificial respiration.
In case of skin contact
Wash off with soap and plenty of water.
In case of eye contact
Flush eyes with water as a precaution.
If swallowed
Never give anything by mouth to an unconscious person. Rinse mouth with water.
Most important symptoms and effects, both acute and delayed
Deoxycytidine has been found to be markedly less toxic than its dideoxy counterpart, dideoxycytidine.
When used in conjunction with some anti-viral chemical therapies, deoxycytidine has been found to
diminish some of the toxic side effects associated with chemotherapy.
Indication of any immediate medical attention and special treatment needed
no data available

Section5. FIREFIGHTING MEASURES
Extinguishing media
Suitable extinguishing media
Use water spray, alcohol-resistant foam, dry chemical or carbon dioxide.
Special hazards arising from the substance or mixture
Carbon oxides, nitrogen oxides (NOx)
Advice for firefighters
Wear self contained breathing apparatus for fire fighting if necessary.
Further information
no data available

Section6. ACCIDENTAL RELEASE MEASURES
Personal precautions, protective equipment and emergency procedures
Avoid dust formation. Avoid breathing vapors, mist or gas.
Environmental precautions
Do not let product enter drains.
Methods and materials for containment and cleaning up
Sweep up and shovel. Keep in suitable, closed containers for disposal.
Reference to other sections
For disposal see section 13.

Section7. HANDLING AND STORAGE
Precautions for safe handling
Provide appropriate exhaust ventilation at places where dust is formed.Normal measures for preventive fire
protection.
Conditions for safe storage, including any incompatibilities
Store in cool place. Keep container tightly closed in a dry and well-ventilated place.
Specific end uses
no data available

Section8. EXPOSURE CONTROLS/PERSONAL PROTECTION
Control parameters
Components with workplace control parameters
Exposure controls
Appropriate engineering controls
General industrial hygiene practice.
Personal protective equipment
Eye/face protection
Use equipment for eye protection tested and approved under appropriate government standards
such as NIOSH (US) or EN 166(EU).
Skin protection
Handle with gloves. Gloves must be inspected prior to use. Use proper glove removal technique
(without touching glove's outer surface) to avoid skin contact with this product. Dispose of
contaminated gloves after use in accordance with applicable laws and good laboratory practices.
Wash and dry hands.
The selected protective gloves have to satisfy the specifications of EU Directive 89/686/EEC and
the standard EN 374 derived from it.
Body Protection
Choose body protection in relation to its type, to the concentration and amount of dangerous
substances, and to the specific work-place., The type of protective equipment must be selected
according to the concentration and amount of the dangerous substance at the specific workplace.
Respiratory protection
Respiratory protection is not required. Where protection from nuisance levels of dusts are desired,
use type N95 (US) or type P1 (EN 143) dust masks. Use respirators and components tested and
approved under appropriate government standards such as NIOSH (US) or CEN (EU).

Section9. PHYSICAL AND CHEMICAL PROPERTIES
Information on basic physical and chemical properties
a) AppearanceForm: solid
b) Odourno data available
c) Odour Thresholdno data available
d) pHno data available
e) Melting point/freezingno data available
point
f) Initial boiling point and no data available
boiling range
g) Flash pointno data available
h) Evaporation rateno data available
i) Flammability (solid, gas) no data available
j) Upper/lowerno data available
flammability or
explosive limits
k) Vapour pressureno data available
l) Vapour densityno data available
m) Relative densityno data available
n) Water solubilityno data available
o) Partition coefficient: n- no data available
octanol/water
p) Autoignitionno data available
temperature
q) Decompositionno data available
temperature
r) Viscosityno data available
s) Explosive propertiesno data available
t) Oxidizing propertiesno data available
Other safety information
no data available

Section10. STABILITY AND REACTIVITY
Reactivity
no data available
Chemical stability
no data available
Possibility of hazardous reactions
no data available
Conditions to avoid
no data available
Incompatible materials
no data available
Hazardous decomposition products
Other decomposition products - no data available

Section11. TOXICOLOGICAL INFORMATION
Information on toxicological effects
Acute toxicity
no data available
Skin corrosion/irritation
no data available
Serious eye damage/eye irritation
no data available
Respiratory or skin sensitization
no data available
Germ cell mutagenicity
Genotoxicity in vitro - mouse - fibroblast
DNA inhibition
Carcinogenicity
IARC:No component of this product present at levels greater than or equal to 0.1% is identified as
probable, possible or confirmed human carcinogen by IARC.
Reproductive toxicity
no data available
Specific target organ toxicity - single exposure
no data available
Specific target organ toxicity - repeated exposure
no data available
Aspiration hazard
no data available
Potential health effects
InhalationMay be harmful if inhaled. May cause respiratory tract irritation.
IngestionMay be harmful if swallowed.
SkinMay be harmful if absorbed through skin. May cause skin irritation.
Eyes
May cause eye irritation.
Signs and Symptoms of Exposure
Deoxycytidine has been found to be markedly less toxic than its dideoxy counterpart, dideoxycytidine.
When used in conjunction with some anti-viral chemical therapies, deoxycytidine has been found to
diminish some of the toxic side effects associated with chemotherapy.
Additional Information
RTECS: HA3830000

Section12. ECOLOGICAL INFORMATION
Toxicity
no data available
Persistence and degradability
no data available
Bioaccumulative potential
no data available
Mobility in soil
no data available
Results of PBT and vPvB assessment
no data available
Other adverse effects
no data available

Section13. DISPOSAL CONSIDERATIONS
Waste treatment methods
Product
Offer surplus and non-recyclable solutions to a licensed disposal company.
Contaminated packaging
Dispose of as unused product.

Section14. TRANSPORT INFORMATION
UN number
ADR/RID: -IMDG: -IATA: -
UN proper shipping name
ADR/RID: Not dangerous goods
IMDG: Not dangerous goods
IATA:Not dangerous goods
Transport hazard class(es)
ADR/RID: -IMDG: -IATA: -
Packaging group
ADR/RID: -IMDG: -IATA: -
Environmental hazards
ADR/RID: noIMDG Marine pollutant: noIATA: no
Special precautions for user
no data available



SECTION 15 - REGULATORY INFORMATION
N/A


SECTION 16 - ADDITIONAL INFORMATION
N/A

毒理学数据:

二、毒理学数据:

急性毒性:不可用。

生态学数据:

三、生态学数据:

1、其它有害作用:该物质对环境可能有危害,对水体应给予特别注意。

CHEMICAL IDENTIFICATION

RTECS NUMBER :
HA3830000
CHEMICAL NAME :
Cytidine, 3'-deoxy-
CAS REGISTRY NUMBER :
7057-33-2
LAST UPDATED :
199612
DATA ITEMS CITED :
1
MOLECULAR FORMULA :
C9-H13-N3-O4
MOLECULAR WEIGHT :
227.25

HEALTH HAZARD DATA

ACUTE TOXICITY DATA

MUTATION DATA

TYPE OF TEST :
DNA inhibition
TEST SYSTEM :
Rodent - mouse Fibroblast
DOSE/DURATION :
1 mg/L
REFERENCE :
CBRPDS Cell Biology International Reports. (Academic Press, Inc., 1 E. First St., Duluth, MN 55802) V.1- 1977- Volume(issue)/page/year: 2,279,1978

RTECS号 HA3830000